Pharming Group (NASDAQ:PHAR – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a report released on Thursday, Benzinga reports. They presently have a $37.00 price target on the stock. HC Wainwright’s target price suggests a potential upside of 325.29% from the stock’s current price.
Pharming Group Stock Up 4.8 %
Shares of NASDAQ:PHAR opened at $8.70 on Thursday. The company has a debt-to-equity ratio of 0.40, a current ratio of 3.39 and a quick ratio of 2.65. The stock has a market cap of $590.12 million, a price-to-earnings ratio of -45.79 and a beta of 0.15. The company has a 50 day moving average of $8.05 and a 200-day moving average of $8.55. Pharming Group has a one year low of $6.65 and a one year high of $13.20.
Pharming Group (NASDAQ:PHAR – Get Free Report) last issued its earnings results on Thursday, August 1st. The company reported ($0.01) EPS for the quarter. Pharming Group had a negative net margin of 4.65% and a negative return on equity of 5.69%. The business had revenue of $74.09 million for the quarter, compared to the consensus estimate of $71.95 million. During the same quarter in the previous year, the firm posted $0.02 EPS. On average, sell-side analysts forecast that Pharming Group will post -0.15 earnings per share for the current year.
Institutional Trading of Pharming Group
About Pharming Group
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Featured Stories
- Five stocks we like better than Pharming Group
- How to Calculate Options Profits
- Texas Roadhouse Stock Steering for New Highs This Year
- What is the Hang Seng index?
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- The Basics of Support and Resistance
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.